Evidence map›Paper›PMID 40843773›Full record

Trial reportDiabetes, obesity & metabolism2025

Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.

Linong Ji, Guoyue Yuan, Jun Liu, Bingjie Zhang, Wenyan Liu, Zewei Shen

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.ORCID https://orcid.org/0000-0003-1305-1598
Guoyue YuanDepartment of Endocrinology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.ORCID https://orcid.org/0000-0003-0822-6066
Jun LiuDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Bingjie ZhangNovo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.
Wenyan LiuNovo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.
Zewei ShenNovo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.

Funding

Novo Nordisk Shanghai (Ltd) N/A
6 · The paper itself

Abstract

aimsThis post hoc analysis investigates the impact of baseline characteristics on the efficacy and safety of oral semaglutide in a Chinese population with type 2 diabetes. MATERIALS AND

methodsChinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once-daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12). Changes from baseline in HbA

resultsIn total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated. Most baseline characteristics were similar across the two trials in the different subgroups. Overall, greater reductions in HbA CONCLUSIONS/

interpretationOral semaglutide reduces HbA

Indexed as

Diabetes Mellitus, Type 2East Asian PeopleGlucagon-Like Peptide 1Hypoglycemic AgentsSitagliptin PhosphateAdministration, OralAdultAgedBlood GlucoseBody WeightChinaDouble-Blind MethodFemaleGlycated HemoglobinHumansMaleBlood GlucoseGlucagon-Like Peptide 1Glycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSemaglutideSitagliptin Phosphatebody weightGLP‐1RAHbA1coral semaglutidesafetytype 2 diabetes

Identifiers

PMID40843773
PMCPMC12515755

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.